PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target

PHAXIAM Therapeutics, announces the launch of a new preclinical development targeting a strong antimicrobial-resistant bacteria, Klebsiella pneumonia.